Latent fusion protein

Details Latent fusion protein Latent fusion protein

2005-09-13

2005-09-13

Andres, Janet (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S198100, C530S350000, C530S351000, C514S002600, C435S069100, C435S069510

Reexamination Certificate

active

06942853

ABSTRACT:
This invention provides a nucleic acid construct comprising a first nucleic acid sequence encoding a pharmaceutically active agent and a second nucleotide sequence encoding a latency associated peptide, in which a nucleic acid sequence encoding a proteolytic cleavage site is provided between the first and second nucleic acid sequences. The invention further provides a fusion protein comprising a latency associated peptide and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent. Also disclosed are processes for preparing the construct and fusion protein, methods of treatment using the construct and fusion protein and pharmaceutical compositions containing the construct and fusion protein.

REFERENCES:
patent: 5697901 (1997-12-01), Eriksson
patent: 5801231 (1998-09-01), Derynck et al.
patent: 6080575 (2000-06-01), Heidtmann et al.
patent: 6670147 (2003-12-01), Heidtmann et al.
patent: 2004/0110682 (2004-06-01), Heidtmann et al.
patent: 738717 (1998-07-01), None
patent: 2227159 (1998-07-01), None
patent: 0 373 994 (1990-06-01), None
patent: 0 704 532 (1996-04-01), None
patent: 2 324 960 (1998-11-01), None
patent: WO 91/08291 (1991-06-01), None
patent: WO 94/26892 (1994-11-01), None
patent: WO 00/20449 (2000-04-01), None
Renauld, J. 2003. Nature Reviews in Immunology, vol. 3(8), pp. 667-676.
Opal et al., Chest, 2000, vol. 117, pp. 1162-1172.
Chernajovsky, Y., et al., “Engineering T cells and molecules for targeting joints and inflammation,”Arthritis Res. 3(suppl.1):A4, Biomed Central, Ltd. (Apr. 2001).
Baugh, M.D., et al., “Matrix Metalloproteinase Levels Are Elevated in Inflammatory Bowel Disease,”Gastroenterology 117:814-822, American Gastroenterological Association (1999).
Brunner, A.M., et al., “Site-directed Mutagenesis of Cysteine Residues in the Pro Region of the Transforming Growth Factor β1 Precursor,”J. Biol. Chem. 264:13660-13664, The American Society for Biochemistry and Molecular Biology, Inc. (1989).
Brunner, A.M., et al., “Site-Directed Mutagenesis of Glycosylation Sites in the Transforming Growth Factor-β1 (TGFβ1) and TGFβ2 (414) Precursors and of Cysteine Residues within Mature TGFβ1: Effects on Secretion and Bioactivity,”Mol. Endocrinol. 6:1691-1700, The Endocrine Society (1992).
Carroll, M.C., “The Role of Complement and Complement Receptors in Induction and Regulation of Immunity,”Annu. Rev. Immunol. 16:545-568, Annual Reviews Inc. (1998).
Chernajovsky, Y., et al., “Efficient Constitutive Production of Human Fibroblast Interferon by Hamster Cells Transformed with the IFN-β1Gene Fused to An SV40 Early Promoter,”DNA 3:297-308, Mary Ann Liebert, Inc. (1984).
Chernajovsky, Y., et al., “Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model,”Gene Ther. 4:553-559, Stockton Press (1997).
Coombs, G.H. and Mottram, J.C., “Parasite proteinases and amino acid metabolism: possibilities for chemotherapeutic exploitation,”Parasitology 114:S61-S80, Cambridge University Press (1997).
Crawford, S.E., et al., “Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo,”Cell 93:1159-1170, Cell Press (1998).
DeClerck, Y.A., et al., “Inhibition of Invasion and Metastasis in Cells Transfected with an Inhibitor of Metalloproteinases,”Cancer Res. 52:701-708, The American Association for Cancer Research (1992).
de Martin, R., et al., “Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family,”EMBO J. 6:3673-3677, IRL Press Ltd. (1987).
Derynck, R., et al., “Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells,”Nature 316:701-705, Macmillan Publishers Ltd. (1985).
Derynck, R., et al., “A new type of transforming growth factor-β, TGF-β3,”EMBO J. 7:3737-3743, IRL Press Ltd. (1988).
Derynck, R., “TGF-β-receptor-mediated signaling,”Trends in Biochem. Sci. 19:548-553, Elsevier Science Ltd. (1994).
Dreja, H., et al., “Soluble Complement Receptor 1 (CD35) Delivered by Retrovirally Infected Syngeneic Cells or by Naked DNA Injection Prevents the Progression of Collagen-Induced Arthritis,”Arthritis&Rheumatism 43:1698-1709, American College of Rheumatology (Aug. 2000).
Eklöv, S., et al., “Lack of the Latent Transforming Growth Factor β Binding Protein in Malignant, but not Benign Prostatic Tissue,”Cancer Res. 53:3193-3197, American Association for Cancer Research (1993).
Gibson, M.A., “Bovine Latent Transforming Growth Factgor β1-Binding Protein 2: Molecular Cloning, Identification of Tissue Isoforms, and Immunolocalization to Elastin-Associated Microfibrils,”Molec. Cell. Biol. 15:6932-6942, American Society for Microbiology (1995).
Goldman, M.H., et al., “Monitoring proteolysis of recombinant human interferon-γ during batch culture of Chinese hamster ovary cells,”Cytotechnol. 23:103-111, Kluwer Academic Publishers (1997).
Gordon, E.M., et al., “Capture and Expansion of Bone Marrow-Derived Mesenchymal Progenitor Cells with a Transforming Growth Factor-β1—von Willebrand's Factor fusion Protein for Retrovirus-Mediated Delivery of Coagulation Factor IX,”Hum. Gene Ther. 8:1385-1394, Mary Ann Liebert, Inc. (1997).
Han, Z., et al., “AP-1 and NF-κB Regulation in Rheumatoid Arthritis and Murine Collagen-Induced Arthritis,”Autoimmunity 28:197-208, Harwood Academic Publishers (1998).
Hanks, S.K., “Amino acid sequence of the BSC-1 cell growth inhibitor (polyergin) deduced from the nucleotide sequence of the cDNA,”Proc. Natl. Acad. Sci. USA 85:79-82, National Academy of Sciences of the USA (1988).
Iwakura, Y., et al., “Purification of Mouse L Cell Interferon,”J. Biol. Chem. 253:5074-5079, The American Society of Biological Chemists, Inc. (1978).
Jakowlew, S.B., et al., “Complementary Deoxyribonucleic Acid Cloning of a Messenger Ribonucleic Acid Encoding Transforming Growth Factor β 4 from Chicken Embryo Chondrocytes,”Molec. Endocrinol. 2:1186-1195, The Endocrine Society (1988).
Janssens, K., et al., “Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati-Engelmann disease,”Nature Genetics 26:273-275, Macmillan Magazines Ltd. (Nov. 2000).
Kanzaki, T., et al., “TGF-β1 Binding Protein: A component of the Large Latent Complex of TGF-β1 with Multiple Repeat Sequences,”Cell 61:1051-1061, Cell Press (1990).
Khalil, N., “TGF-β: from latent to active,”Microbes and Infection 1:1255-1263, Elsevier (1999).
Kojima, S., et al., “Requirement for Transglutaminase in the Activation of Latent Transforming Growth Factor-β in Bovine Endothelial Cells,”J. Cell Biol. 121:439-448, The Rockefeller University Press (1993).
Kondaiah, P., et al., “Identification of a Novel Transforming Growth Factor-β (TGF-β5) mRNA inXenopus laevis,”J. Biol. Chem. 265:1089-1093, The American Society for Biochemistry and Molecular Biology, Inc. (1990).
Kubota, E., et al., “Interleukin 1β and Stromelysin (MMP3) Activity of Synovial Fluid as Possible Markers of Osteoarthritis in the Temporomandibular Joint,”J. Oral Maxillofac. Surg. 55:20-27, American Association of Oral and Maxillofacial Surgery (1997).
Leppert, D., et al., “Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis,”Brain 121:2327-2334, Oxford University Press (1998).
Libby, P., “The interfce of atherosclerosis and thrombosis: basic mechanisms,”Vasc. Med. 3:225-229, Arnold (1998).
Lode, H.N., et al., “Immunocytokines: A Promising Approach

Affiliated with

Also associated with

Rating

Latent fusion protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Latent fusion protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Latent fusion protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3370986